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a b s t r a c t
Neuroblastoma is a pediatric cancer of the developing sympathoadrenal lineage. The tumors are known
to develop from the adrenal gland or paraspinal ganglia and have molecular and cellular features of
sympathetic neurons such as dense core vesicles and catecholamine production. Here we present the
detailed molecular, cellular, genetic and epigenetic characterization of an orthotopic xenograft derived
from a high-risk stage 4 neuroblastoma patient. Overall, the xenografted tumor retained the high risk
features of the primary tumor and showed aggressive growth and metastasis in the mouse. Also, the
genome was preserved with no additional copy number variations, structural variations or aneuploidy.
There were 13 missense mutations identiﬁed in the xenograft that were not present in the patient's
primary tumor and there were no new nonsense mutations. None of the missense mutations acquired in
the xenograft were in known cancer genes. We also demonstrate the feasibility of using the orthotopic
neuroblastoma xenograft to test standard of care chemotherapy and molecular targeted therapeutics.
Finally, we optimized a new approach to produce primary cultures of the neuroblastoma xenografts for
high-throughput drug screening which can be used to test new combinations of therapeutic agents for
neuroblastoma.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Neuroblastoma is the most common extracranial solid tumor
and the most common tumor in infants (Maris et al., 2007). The
course of the disease is variable with some tumors regressing
spontaneously and others progressing rapidly despite intense
therapeutic intervention (Cheung and Dyer, 2013). Current treat-
ment includes chemotherapy, surgical resection, radiotherapy,
stem cell transplantation, and immunotherapy (Maris, 2010).
While low-risk patients may be cured with surgery alone, patients
with high-risk neuroblastoma have a poor prognosis despite this
aggressive therapy (Maris, 2010).
Neuroblastoma typically arises in the retroperitoneum from the
adrenal glands and paravertebral sympathetic plexus. It is a highly
vascular tumor that wraps around major abdominal vessels,
developing extensive tumor neovasculature (Chlenski et al.,
2003; Maris et al., 2007). This suggests activation of angiogenic
signaling pathways, many of which are regulated through receptor
tyrosine kinase (RTK) signaling cascades. For example, the phos-
phatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapa-
mycin (mTOR) (PI3K/AKT/mTOR) pathway is a pro-survival
signaling cascade that is aberrantly activated in neuroblastoma
and activation correlates with a poor prognosis (Opel et al., 2007).
mTOR regulates cell growth and autophagy, and its activity in
neuroblastoma cells has been shown to affect cell differentiation
by coordinating macromolecule synthesis and degradation (Zeng
and Zhou, 2008). Targeted agents including monoclonal antibo-
dies, small molecule tyrosine kinase inhibitors and serine-
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threonine kinase inhibitors can block this pathway at multiple
regulatory nodes (Segerstrom et al., 2011). Indeed, therapeutics
targeting PI3K/AKT/mTOR have shown efﬁcacy in preclinical
models of neuroblastoma (Chanthery et al., 2012) and may be a
promising approach for patients with high-risk disease.
We previously developed an ultrasound guided, minimally
invasive method for injecting neuroblastoma cell lines into the
adrenal gland or para-adrenal space of immunocompromised mice
(Teitz et al., 2011). This model was used to test a standard-of-care
induction chemotherapy regimen, which includes cyclophospha-
mide, doxorubicin, and etoposide with alternating courses of
cisplatin and etoposide (Teitz et al., 2011). Tumor growth and
response was monitored using ultrasound, MRI and biolumines-
cence imaging. 30% of the mice treated with induction chemother-
apy demonstrated a clinical response with complete response (CR)
or stable disease (SD). Animals with SD or CR could be differ-
entiated by the 5th course. This was reminiscent of observations in
clinical trials, which supported reduction of the number of cycles
of intensive induction chemotherapy previously used for high-risk
neuroblastoma (Kushner et al., 2004).
A major challenge in oncology research is the low success of
translating preclinical results to effective outcomes in patients.
This discrepancy can result from many different factors including
the dose, schedule and combination of drugs used in preclinical
testing, the method for monitoring and reporting tumor response
and the relevance of the animal models used in preclinical trials.
Orthotopic neuroblastoma xenografts have previously been shown
to be more likely to develop distant metastasis compared to
subcutaneous tumors (Khanna et al., 2002), and others have
adopted similar techniques to create patient-derived xenografts
that retained the major characteristics seen in the patient
(Braekeveldt et al., 2015). Indeed, Braekeveldt et al. (2015) have
shown that patient-derived neuroblastoma xenografts retain the
genetic and histopathologic features of the patient tumor they
were derived from. In this study, we report the development and
characterization of an orthotopic neuroblastoma xenograft from a
high-risk primary patient tumor. We performed comprehensive
genomic characterization of the primary tumor and the xenograft.
As shown previously (Braekeveldt et al., 2015), our patient-derived
neuroblastoma xenograft retained the genetic features of the
primary tumor. To establish a baseline response, we tested
standard of care induction chemotherapy (Matthay et al., 1999)
and compared those data to molecular targeted therapy directed
at the PI3K/AKT/mTOR pathway. We developed a double blind,
randomized preclinical trial design along with an integrated
database using OpenClinica for storing and sharing all preclinical
data. Having validated the xenograft and establishing the value for
preclinical testing, we then developed culture conditions for high
throughput screening of the primary xenograft cells to identify
novel therapeutics. This example serves as the foundation for a
larger more comprehensive effort to establish and characterize
orthotopic xenografts for pediatric solid tumors as a tool for
translational research.
2. Results
2.1. Characterization of a high-risk primary neuroblastoma tumor
sample
We have previously described a method for orthotopically
implanting neuroblastoma cell lines into immunocompromised
mice (Teitz et al., 2011). One disadvantage of using cell lines to
model neuroblastoma in vivo is that they may undergo selection in
culture and the genomic landscape may deviate from the primary
patient tumor (Sausen et al., 2013). Therefore, to more accurately
model neuroblastoma in preclinical models, we developed a
biology protocol called Molecular Analysis of Solid Tumors (MAST)
to obtain excess tumor from surgical resection or biopsy for
orthotopic implantation in immunocompromised mice.
The ﬁrst neuroblastoma orthotopic xenograft from the MAST
protocol came from a 2 year old patient (SJNBL046_D) that
originally presented with a history of intermittent fevers, abdom-
inal distention, fatigue and a limp. Imaging revealed a large
adrenal mass consistent with neuroblastoma. Urine catechola-
mines were elevated and there was evidence of metastatic lesions
in the lymph nodes and bones. Biopsy conﬁrmed neuroblastoma
with MYCN ampliﬁcation and unfavorable histology (INSS stage 4)
(Fig. 1A–C). The patient had a poor response to the ﬁrst two
courses of induction chemotherapy with cyclophosphamide/dox-
orubicin/etoposide alternating with cisplatin/etoposide. Therefore,
the patient was switched to a cyclophosphamide/topotecan regi-
men. The tumor was resected after 2 cycles of these agents and a
small specimen was dissociated, suspended in matrigel and
injected into the para-adrenal space of NOD scid gamma (NSG)
mice as described previously (Teitz et al., 2011). The patient tumor
specimen used for orthotopic implantation had cellular features of
neuroblastoma including expression of synaptophysin and chro-
mogranin (Fig. 1D–F) as well as abundant dense core vesicles in
electron micrographs, which are a hallmark of catecholamine
storage (Fig. 1G and H).
We characterized the genomic landscape of the patient's tumor
(SJNBL046_D) and germline by whole genome sequencing as
described previously (Cheung et al., 2012). The genome of
SJNBL046_D was typical of high-risk stage 4 MYCN ampliﬁed
neuroblastoma (Fig. 1I). Gene expression array analysis of
SJNBL046_D and the xenografts derived from the patient tumor
(see below) was similar to other MYCN ampliﬁed neuroblastomas
(Fig. 1J).
2.2. Characterization of a neuroblastoma orthotopic xenograft
Six months after initial implantation into the para-adrenal space
of NSG mice (Fig. 2A–C), we identiﬁed a mass consistent with
neuroblastoma, which was conﬁrmed by ultrasound. The animal
was euthanized and the primary tumor at the site of injection was
removed (Fig. 2D). We also identiﬁed metastatic lesions in the liver
with extensive inﬁltration (Fig. 2E). Histopathological and transmis-
sion electron microscopic analyses conﬁrmed that the orthotopic
xenograft (SJNBL046_X) had cellular features of the patient's tumor
(SJNBL046_D) (Fig. 2F–J). The tumor cells on the liver were inﬁltrat-
ing and invading the normal liver tissue (Fig. 2K–M). The dissociated
tumors were cryopreserved and also injected into an additional
cohort of NSG mice to expand and propagate the xenograft. With
subsequent passage, the tumors grewmore rapidly (4–6 weeks) than
the original diagnostic tumor.
In addition to the cellular and histological characterization, we
also performed detailed molecular and genomic proﬁling of
SJNBL046_X. SNP 6.0 analysis of the patient's germline DNA,
diagnostic tumor (SJNBL046_D), primary and metastatic xeno-
grafts (SJNBL046_X) showed that they retained MYCN ampliﬁca-
tion and the other chromosomal lesions (chromosomes 1, 15 and
17) found in the diagnostic tumor (Fig. 3A). More importantly,
SJNBL046_X did not acquire any additional large chromosomal
gains or losses. Spectral karyotype analysis (SKY) conﬁrmed these
results and provided additional information on the chromosomal
lesions (Fig. 3B). In particular, fragments of chromosome 17 that
were gained in SJNBL046 were fused to chromosome 13 and 22.
The gain on chromosome 1 was fused to chromosome 7 and
portions of chromosome 7 and 15 were fused to chromosome 1.
The MYCN ampliﬁcation was a double minute as validated by
ﬂuorescence in situ hybridization (FISH) (Fig. 3C). A comparison of
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Fig. 1. Characterization of the primary SJNBL046 tumor. (A) Micrograph of hematoxylin and eosin (H&E) stained needle biopsy of the diagnostic tumor prior to treatment. (B
and C) Synaptophysin and chromogranin immunohistochemical staining (brown) of the needle biopsy specimen shown in (A). (D–F) Micrographs of H&E, synaptophysin and
chromograning immunohistochemical staining of the patient tumor at the time of surgical resection (SJNBL046_D). (G and H) Electron micrographs of SJNBL046_D with
dense core vesicles (DCV, arrows). (I) Circos plot of whole genome sequencing of SJNBL046_D. Loss of heterozygosity (orange), copy number gain (red), and losses (blue) are
shown. Intrachromosomal translocations (green lines) and interchromosomal translocations (purple lines) are indicated. Sequence mutations in Refseq genes included silent
single nucleotide variants (SNVs, green), nonsense and missense SNVs (brown), splice-site and UTR mutations (dark blue), and insertion/deletion mutations (red).
(J) Principle component analysis of gene expression arrays for the SJNBL046_D sample and 3 xenografts (SJNBL046_X) derived from SJNBL046_D. This includes an early
passage, a late passage and a matched metastatic lesion of SJNBL046_X. Abbreviations: H&E, hematoxlyin and eosin; DCV, dense core vesicles; m, mitochondria. Scale bars:
A–F: 50 mm.
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the gene expression array data of the diagnostic tumor
(SJNBL046_D) and the orthotopic xenograft (SJNBL046_X) showed
a correlation coefﬁcient of 0.92 (Fig. 3D). The most signiﬁcant
upregulated genes in the xenograft were associated with cell cycle
and the most downregulated genes were associated with extra-
cellular matrix organization and cell adhesion (Supplemental
information).
We also performed whole exome sequencing of the orthotopic
xenograft and compared the exonic single nucleotide variations
(SNVs) in the xenograft to those identiﬁed in the diagnostic tumor
by whole genome sequencing (Cheung et al., 2012). We identiﬁed
a series of missense and nonsense mutations in genes that arose in
the xenograft and were not present in the diagnostic tumor
(Fig. 3E and Table S1) but very few were in known cancer genes
or have been found to be recurrently mutated in neuroblastoma.
We also performed DNA methylation analysis using the Illumina
450k beadplex platform on the diagnostic tumor, and the xeno-
grafts from the primary and metastatic sites. There was good
Fig. 2. Establishing an orthotopic xenograft of SJNBL046. (A) Drawing of method for para-adrenal injections. The injection procedure is a closed procedure using ultrasound
guidance. (B) Ultrasound image of needle immediately after deposition of SJNBL046_D cells in matrigel (red) adjacent to the adrenal gland (blue). (C) 3D reconstruction of the
kidney (green), adrenal gland (blue) and deposited tumor cells in matrigel (red). (D) Photograph of a large primary SJNBL046_X mass surrounding the adrenal and kidney
and expanding into the abdominal cavity. (F and G) Low and high power micrographs of H&E stained sections of the SJNBL046_X tumor. (H and I) Micrographs of
chromogranin and synaptophysin immunohistochemical staining of sections of SJNBL046_X. (J) Transmission electron micrograph of SJNBL046_X showing dense core
vesicles (inset arrows). (K and L) Micrographs of chromogranin and synaptophysin staining of metastatic lesions from SJNBL046_X in the liver. (M) Electron micrograph of
metastatic SjNBL046_X cells invading the liver (red shading). Scale bars: F, H, I, K, L: 50 mm; G: 10 mm.
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Fig. 3. Characterization of the SJNBL046 xenograft. (A) Diagram of copy number variations from SNP 6.0 analysis of the SJNBL046_D tumor and a sample from the primary
site of engraftment (para-adrenal) and a metastatic site (liver). Copy number gains are shown in red and losses are shown in blue. The MYCN ampliﬁcation is indicated with
an arrow. (B) Spectral karyotype analysis of SJNBL046_X showing the MYCN ampliﬁcation on a double minute fragment and several translocations, losses and gains. The SKY
analysis agrees with the copy number analysis in (A). (C) Fluorescence in situ hybridization for MYCN in a metaphase SJNBL046_D cell. The DNA fragments that hybridized to
the MYCN probe are shown in green and the metaphase chromosomes are stained with DAPI (blue). (D) Scatterplot of correlation in gene expression arrays for SJNBL046_D
and SJNBL046_X with a 0.92 correlation coefﬁcient. (E) Circos plot showing the coding region single nucleotide variations (SNV) across SJNBL046_D and SJNBL046_X. Those
genes with SNVs in both the SJNBL046_D and SJNBL046_X samples are shown in black and those unique to SJNBL046_X are in blue. (F) Heat map of correlation of DNA
methylation (Illumina 450K) across SJNBL046_D and two SJNBL046_X samples (primary and metastatic). Abbreviations: SNV, single nucleotide variation.
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agreement between the primary tumor and each xenograft with
93% and 91% correlation (Fig. 3F and Table S2). There was 98%
correlation between the two xenograft samples from the primary
and metastatic sites (Fig. 3F and Table S2).
2.3. Targeting the PI3K/AKT/mTOR pathway in SJNBL046_X
Neuroblastomas are highly vascular tumors that often wrap
around major abdominal vessels. Activation of the PI3K/AKT/mTOR
pathway frequently occurs in neuroblastoma and correlates with a
poor prognosis (Opel et al., 2007). mTOR is an important regulator
of cell growth and autophagy, and its activity in neuroblastoma
cells has been shown to impact cell differentiation by regulating
the balance between macromolecule synthesis and degradation
(Zeng and Zhou, 2008). Moreover, preclinical studies have shown
that small molecule inhibitors of this pathway can have an anti-
angiogenic effect on neuroblastoma in vivo (Chanthery et al.,
2012). To establish a standardized procedure for preclinical testing
of novel therapeutics, we developed an integrated database using
OpenClinica. We performed a randomized, double blind study
comparing standard of care chemotherapy and molecular targeted
therapy for the PI3K/AKT/mTOR pathway. For standard of care
(SOC), the ﬁrst course of chemotherapy was cyclophosphamide,
doxorubicin and etoposide (CAE) and the second course was
etoposide and cisplatin (CE) (Supplemental information). Alter-
nating CAE/CE treatments were repeated for a total of 4 courses
over 12 weeks (Fig. 4A and B). To target the PI3K/AKT/mTOR
pathway, we treated mice for 2 courses with SOC followed by OSI-
906 with BEZ235 or OSI-906 with BKM120 on a dailyx5 schedule
(Fig. 4C and D). OSI-906 is a small molecule inhibitor of the IGFR1
receptor, BEZ235 is a small molecule inhibitor of PI3K and mTOR
and BKM120 is a pan-PI3K inhibitor. The IGFR1 receptor signals
through the PI3K/AKT/mTOR pathway. All three drugs are cur-
rently in clinical development for cancer patients and we used
plasma pharmacokinetics to achieve clinically relevant doses in
mice (data not shown).
Initially, 120 mice received para-adrenal injections of 10 ml
SJNBL_046X in matrigel (20,000 cells/ml). The mice were mon-
itored weekly by ultrasound and when the tumor volume was 6–
8 mm3, they were assigned a mouse medical record number
(mMRN) and enrolled on study (Supplemental information). A
total of 80 mice were enrolled on the study (20 per treatment
group) and we used a randomized double blind preclinical trial
design (Supplemental information). The mice were randomized to
4 treatment groups (placebo, SOC, OSI-906þBEZ235 and OSI-
906þBKM120) and were treated for 4 courses (12 weeks)
(Fig. 4A–D). The tumor volume was measured every 3 weeks by
ultrasound and animals were euthanized when tumor burden
reached 20% of body weight. MRI was also used to validate the
ultrasound volumetric data (Supplemental information). When
the animals were euthanized at the end of study or due to
progressive disease, the tumors were processed and embedded
for histopathological analysis.
Survival times among the four groups showed signiﬁcant
differences using the log-rank test (p¼0.001) or the Gehan–
Wilcoxon test (po0.001) and each of the 3 treatment arms were
signiﬁcantly different from the placebo group (Fig. 4E). However,
pairwise comparison of the survival times between the treatment
arms were not statistically signiﬁcant (Supplemental information).
The OSI-906þBKM120 treatment arm had greater mean and
median survival time compared to all other treatment arms
(Fig. 4E and Supplemental information). We quantitated the rate
of change in tumor volume by calculating the doubling time
between two successive pairs of volumetric measurements using
ultrasound (Fig. 4F–K). In the SOC treatment arm, 23% of the
tumors diminished in size, 7% remained stable and 70% showed
slower growth compared to placebo (placebo: 471 days vs. SOC:
16711 days, po0.001). None of the tumors in the placebo group
decreased in size or regressed during the study. There was no
signiﬁcant difference in growth doubling times among any of the
treatment groups (Fig. 4G–I).
To relate the tumor response across treatment arms to cellular
mechanisms of each drug combination, we performed histopatho-
logical analysis of the tumors. From the 80 mice enrolled on study,
there were 51 tumors available for analysis. For each tumor, 4 mm
sections were cut to prepare 115 slides for each tissue block for a
total of 5865 slides for this study. We used three sets of 5 serial
slides per tumor with 200 mm between each set. Sequential slides
in each set were stained with Ki67 to monitor proliferation,
phospho-histone H3 to monitor M-phase, activated caspase 3 to
monitor cell death, Mac2 to monitor macrophage inﬁltration and
CD34 to monitor tumor vasculature (Fig. 5A). Each slide was
digitally scanned and then linked to the individual mouse data
in OpenClinica. An image processing pipeline was developed to
quantitate proliferation, apoptosis, angiogenesis, macrophage inﬁl-
tration and necrosis in each of the 51 tumors (Supplemental
information).
Our automated image processing pipeline was used to segment
the tumor tissue scans and measure the area of viable tumor,
ischemic necrosis, long standing necrosis, extracellular matrix/
stroma/fat, tissue folds, liver, kidney, spleen, muscle and glass
based on the texture and H&E staining properties (Fig. 5B–D and
Supplemental information). The algorithm achieved greater than
95% accuracy per region in cross-validation tests (Supplemental
information). SJNBL_046X is a fast growing tumor that outgrows
its vasculature and has large areas of necrotic tissue in untreated
mice. The viable-to-total-necrotic tissue ratio was signiﬁcantly
higher in the SOC and OSI-906þBEZ235 treatment groups
(po0.001) (Fig. 5E) and this is consistent with previous reports
that apoptosis and necrosis are inversely correlated in rapidly
growing tumors such as SJNBL_046X (Arends et al., 1994). Both the
SOC and OSI-906þBKM120 treatment arms showed increased
levels of pH3 and Ki67 relative to placebo when normalized to
the viable tumor area (Fig. 5E). In addition to inhibiting PI3K, it has
been reported that BKM120 can induce G2/M-phase arrest
(Brachmann et al., 2012). Consistent with this observation, the
pH3/Ki67 ratio was higher in OSI-906þBKM120 treated tumors
compared to placebo or OSI-906þBEZ235 (Fig. 5F). The proportion
of apoptotic cells (activated caspase 3 immunopositive) was
signiﬁcantly higher in the viable tumor regions for the OSI-
906þBKM120 treatment arms compared to placebo (Fig. 5G).
The other treatment arms did not reach statistical signiﬁcance. It
has been previously reported that targeting the PI3K/AKT/mTOR
pathway in tumor models in vivo can have anti-angiogenic effects
(Chanthery et al., 2012; Cho et al., 2010; Guba et al., 2002).
Consistent with these previous reports, the OSI-906þBEZ235
and OSI-906þBKM120 treatment arms showed signiﬁcant reduc-
tion in CD34 immunostaining for tumor vasculature in the viable
regions of the tumor (Fig. 5H). Finally, we analyzed macrophage
inﬁltration in the viable and necrotic regions of the tumor. There
was a signiﬁcant reduction in macrophages in both viable and
necrotic regions of tumors treated with OSI-906þBEZ235 and OSI-
906þBKM120 (Fig. 5I).
2.4. High throughput screening of primary neuroblastoma xenograft
To determine if the human neuroblastoma orthotopic xenograft
described here (SJNBL046_X) could be used for testing drug
sensitivity, we developed a method for dissociating and plating
tumor cells in 384 well plates. Brieﬂy, the tumor is dissociated into
a single cell suspension with trypsin and ﬁltered through a cells
strainer to remove debris (Fig. 6A, Day 0). The contaminating red
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Fig. 4. Preclinical testing using SJNBL046_X. (A–D) Diagram of the dosing schedule for standard of care chemotherapy (CAE, CE) and therapy targeting the PI3K pathway. (C
and D) Drug doses were AUC guided based on pharmacokinetic studies performed on mice and humans. (E) Kaplan–Meier curves for each of the treatment groups. All mice
in treatment groups received standard of care (SOC) for the ﬁrst 2 courses (black shading). The placebo group received no treatment during these ﬁrst 2 courses (red line).
After the ﬁrst 2 courses, one cohort continued on with SOC treatment and the other groups received the speciﬁed PI3K targeted therapy. (F–I) Estimated doubling time from
the analysis of tumor volume and immunhistochemical staining for each treatment group at each course of treatment. Statistical analysis is presented in the Supplemental
information. Representative ultrasound image and 3D reconstruction of a tumor with complete response (J) and progressive disease (K).
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blood cells are eliminated and the tumor cells are plated in 384
well dishes in matrigel. Once the matrigel polymerizes, the cells
are overlaid with cell culture medium (Supplemental information)
and placed in a cell culture incubator (Fig. 6A). Twenty four hours
later drugs are added in triplicate dose response using a pin tool
(Fig. 6A, Day 1). Seventy two hours later, cell titer glow is added to
the plate and the ATP levels are quantitated on a plate reader
(Fig. 6A, Day 4). Positive and negative control compounds are
included in each experiment for data normalization. Validated
data are then entered into a central database and curve ﬁtting is
performed to generate an EC50 for each drug (Fig. 6B and C).
Overall, the SJNBL046_X cells are much less sensitive to
Fig. 5. Histological analysis of SJNBL046_X tumors after treatment. (A) Drawing of the scheme used to sample the tumor tissue isolated from mice that came off of study.
Three regions of tumor were processed separately and serial sections were collected to produce 3 distinct sets for each tumor. After staining, the slides were scanned and
images were segmented and scored using the automated system described in the Supplemental information. (B) Representative H&E stained section of a SJNBL046_X tumor
and the matched segmentation and automated scoring of the tissue for viable (red), ischemic necrotic (orange) and long-standing necrotic tissue (yellow). (C) Representative
micrographs of immunohistochemical staining of a tumor from a mouse who received placebo and one that received BEZ-235þOSI-906. Arrows indicate immunopositive
cells for each antibody. Scale bars: 50 mm. Abbreviations: Ki67 labels the nuclei of proliferating cells in any stage of the cell cycle. PH3 labels cells in S-phase. Casp3 labels cells
undergoing cell death. CD34 labels vascular endothelial cells and MAC2 labels macrophages.
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chemotherapy than neuroblastoma cell lines. The most sensitive
cell line analyzed in this study was IMR32 and SK-N-AS was the
least sensitive. These data demonstrate the feasibility of perform-
ing high throughput drug screening with a primary orthotopic
neuroblastoma xenograft.
3. Materials and methods
3.1. Mast protocol and patient samples
The study, Molecular Analysis of Solid Tumors (MAST), is a
biology study at St. Jude Children's Research Hospital designed to
prospectively characterize the molecular, cellular and genetic
properties of primary and metastatic pediatric solid tumors.
Additionally, if a participant agrees, it allows for the establishment
of cell lines and xenograft models. Patients are eligible to partici-
pate if they have a solid malignancy and are less than or equal to
25 years old. The MAST protocol was approved by the institutional
review board of St. Jude Children's Research Hospital and the
parents of SJNB046 provided written informed consent in accor-
dance with institutional and federal guidance.
3.2. Immunohistochemistry and TEM analysis
The formalin-ﬁxed-parafﬁn-embedded block of the xenograft
tissue was cut at 4μm sections and processed for immunohisto-
chemistry using heat-induced epitope retrieval with ER1 for 20–
Fig. 6. High-throughput screening of SJNBL046_X primary cultures. (A) Drawing of the scheme used for primary cultures of orthotopic xenografts in the screening platform.
On day 0, the tumor is isolated and processed into a single cell suspension that is then plated into 384 well dishes. The next day (Day 1) the dishes are drugged in dose
response in triplicate and then incubated for 72 h. Cell-titer glo is used to measure the level of ATP in the cultures as a proxy for the number of viable cells. (B) Representative
dose response curves for some of the active drugs against neuroblastoma cell lines and the SJNBL046_X xenograft. (C) Heatmap of the entire drug library tested in this study.
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30 min. Mouse monoclonal antibodies against synaptophysin
(27G12; Leica Microsystems) and chromogranin A (LK2H10(3);
Leica Microsystems) were applied at 1:200 dilution with 15-min
incubation at room temperature using the Leica Bond (Leica
Microsystems) staining platform and the Bond Reﬁne Polymer
detection kit.
3.3. WGS and WES
Whole-genome sequencing (WGS) and SNP or gene expression
proﬁling by array were performed as previously described (Zhang et
al., 2012a, 2012b). For WGS, paired-end sequencing was performed
using the Illumina GAIIx or HighSeq platform with 100 bp read
length. The WGS data are deposited at the European Bioinformatics
Institute (EBI) with accession number EGAS00001000256. WGS
mapping, coverage and quality assessment, single nucleotide varia-
tion (SNV)/indel detection, tier annotation for sequence mutations,
prediction of deleterious effects of missense mutations, and identiﬁ-
cation of loss of heterozygosity (LOH) have been described previously
(Zhang et al., 2012b) Structural variations (SVs) were analyzed using
CREST and annotated as previously described (Wang et al., 2011;
Zhang et al., 2012b). The reference human genome assembly NCBI
Build 36 was used for mapping 5 samples (SJRHB001–005) and Build
37 was used for mapping other samples. Genomic coordinates for
variations in samples mapped to Build 36 were lifted over to Build 37.
Copy number variations (CNVs) were identiﬁed by evaluating the
difference of read depth for each tumor and its matching normal
using a novel algorithm, COpy Number SEgmentation by Regression
Tree In Next-Gen sequencing (CONSERTING).
For whole exome sequencing (WES), DNA libraries were pre-
pared from 1 μg of whole genome ampliﬁed (WGA) material from
matched samples using the Illumnia TruSeq DNA library prep kit
following the recommended manufacturer's protocol. Libraries
were analyzed on an Agilent Bioanalyzer to inspect quality of
each library construction. Germline and diagnostic library samples
were independently pooled and applied for exome capture using
the Illumina TruSeq Exome Enrichment kit as described by the
manufacturer. Captured libraries were then clustered on the
Illumina c-bot and were sequenced on an Illumina HiSeq 2000
platform with 100 base pair end multiplexed reads at an equiva-
lent of 3 samples per lane.
For enrichment and validation of the regions containing puta-
tive alterations, genomic coordinates of the putative WGS targets
were used to order either Nimbelgen Seqcap EZ solution bait sets
(Roche), or Nimblegen Seqcap 2.1M arrays (Roche). The library
construction and target enrichment was performed per manufac-
turer's instructions (Roche) using repli-G (Qiagen) WGA DNA.
Enriched targets were sequenced on the illumina platform using
paired end 100 cycle sequencing. The resulting data was converted
to FASTQ ﬁles using CASAVA 1.8.2 (Illumina), and mapped with
BWA prior to pipeline analysis.
Putative SNVs from exon sequencing were validated by NGS
amplicon sequencing. Brieﬂy, primers were designed to genomic
regions (hg19) ﬂanking the SNV no closer than 100 base pairs to the
detected SNV. PCR was performed using 20–30 ng of whole genome
ampliﬁed (WGA) DNA from each patient sample. DNA from the
tumor (diagnostic sample) and a matched germline sample were
used for each primer set to conﬁrm the presence of the SNV in the
diagnostic sample. Standard PCR was performed in 25 μl reactions
using Accuprime GC-rich DNA polymerase (Invitrogen) with the
following parameters: 95 1C for 3 min, 35 cycles of 95 1C for 30 s,
65 1C for 30 s, 72 1C for 1 min followed by a 72 1C 10 min extension
with cooling to 4 1C. All PCR amplicons were checked on a 2% E-gel
(Invitrogen) to ensure single ampliﬁed products.
PCR ampliﬁed products were collected into diagnostic or germ-
line pools and puriﬁed using a Qiagen PCR puriﬁcation kit. One
nanogram of pooled sample was treated for sequencing using the
Nextera XT kit (Illumina) following the manufacturer's protocol.
Samples were normalized and denatured prior to the MiSeq run
using the 2150 base pair run (version 1) reagent kit.
3.4. Gene expression array analysis
RNA from the primary tumor (SJNBL046_D) and xenograft
(SJNBL046_X) were assayed with the Affymetrix HT HG-U133þ
PM Array Plate (NIH GEO Platform GPL13158). The data was then
RMA summarized (Irizarry et al., 2003) using Partek Genomics
Suite 6.12 (St Louis, MO). Scatterplots, log2ratios and correlations
were produced using STATA/MP 11.2 (College Station, TX).
SJNB046_D/X data was joined by probeset sequence to 125 public
human neuroblastoma microarrays analyzed as previously
described (Teitz et al., 2011). After platform corrected the joined
data set was visualized by principal component analysis (PCA)
using Partek 6.6.
3.5. SNP 6.0 analysis
SJNBL046 germline, primary tumor, xenograft and metastasis
sample DNA was assayed on GenomeWideSNP_6 Affymetrix
arrays. The data was normalized and logratio and copy number
were estimated using the Partek Genomics Suites 6.3 workﬂow.
Data was then visualized in Spotﬁre DecisionSite.
3.6. Ultrasound guided para-adrenal injection
All ultrasound procedures were performed using the VEVO-
770, ﬁtted with a RMV-706 probe. Cells were suspended in
Matrigel (BD Worldwide, Cat#354234) at a concentration of
2104 cells per microliter and placed on ice. Anesthetized
recipient CD1 nude mice (isoﬂurane 1.5% in O2 delivered at 2 l/
min) were placed laterally on the imaging bed such that the left
ﬂank faced upward. In order to provide a channel for delivery of
the implant, a 22 gauge catheter (BDWorldwide, Cat#381423) was
gently inserted through the skin and back muscle into the para-
adrenal region and the hub was removed. A chilled Hamilton
syringe ﬁtted with a 27 gauge needle (1.5 in.) and loaded with
10 ml of the cell suspension was guided steretoactically through
the catheter and positioned between the kidney and adrenal gland
as visualized using ultrasound. The cells were injected into the
region and the needle was left in place for 30 s to permit the
matrigel component to set. The needle was then slowly removed,
followed by gentle removal of the catheter.
3.7. Neuroblastoma xenograft dissociation and banking
Tumor was harvested from SJNB046_X tumor bearing NSG
mice. Tumor was minced with sterile scalpels and rinsed in
phosphate buffered saline without calcium or magnesium (PBS).
Tumor suspension was transferred to a 50 ml conical tube and
ﬁlled with PBS. Dissociation was done by adding 600 ml of trypsin
(10 mg/ml, Sigma Cat#T9935) and the tube was incubated 37 1C
for 10 min. Dissociation was stopped by adding 600 ml of Soybean
Trypsin Inhibitor (10 mg/ml, Sigma Cat#T6522). Deoxyribonu-
clease I (2 mg/ml, Sigma Cat#D4513) and magnesium chloride
(1 M) were added in equal amounts of 60 μL increments until
tumor fragments easily settle at the bottom of the tube. The
dissociated tumor cell suspension was ﬁltered with a 40 mm cell
strainer and then centrifuged at 450g (G¼RCF) for 5 min. Super-
natant was discarded and 10 ml of red blood cell lysis solution (5
Prime Cat#2301310) added and incubated at room temperature for
10 min. PBS with 10% FBS (Biowest Cat#SO1520) was added to ﬁll
50 ml conical tube and cell suspension was centrifuged at 450g
E. Stewart et al. / Developmental Biology 407 (2015) 344–355 353
(G¼RCF) for 5 min. The supernatant was discarded and the cell
pellet was resuspended in PBS/10% FBS for counting.
3.8. SKY
After a 4 h colcemid incubation, cells from this sample were
harvested using routine cytogenetic methods. A commercially
prepared SKY probe from Applied Spectral Imaging (Carlsbad,
CA) was used as the probe for this analysis. Applied Spectral
Imaging protocols were followed for the hybridization and detec-
tion steps. Sixteen metaphase cells were analyzed which were
determined to be male in origin. 69% of analyzed metaphase cells
were found to have the following karyotype determined by SKY as
45,XY,t(1;7)(q?21;p?13)der(1)t(1;15)(p?31;?),der(13)t(13;17)(p?
13;?),-17,der(22)t(17;22)(?;p?13),dmin(2). The remaining 31% of
analyzed metaphase cells were found to have the following
karyotype determined by SKY analysis as 46,XY,t(1;7)t(q?21;p?
13)der(1)t(1;15)(p?31;?),der(13)t(13;17)(p?13;?),der(22)t(17;22)
(?;p?13),dmin(2).
4. Discussion
In this study, we describe the detailed characterization of a patient
derived orthotopic xenograft of a high risk pediatric neuroblastoma
tumor. This is one example of a broader collection of more than 50
orthotopic xenografts of pediatric solid tumors that are made avail-
able to the research community free of charge through the childhood
solid tumor network (CSTN). Not only are these preclinical models of
pediatric cancer useful for studying the basic biology of their
respective diseases, but they can be used for preclinical testing and
high-throughput drug screening of primary cultures derived from the
xenografts. Moreover, they provide a well-validated and renewable
source of cells for future epigenetic and proteomic studies that are
difﬁcult to carry out on primary patient tumors.
4.1. Orthotopic xenografts preserve features of primary tumor
Many key features of the high-risk neuroblastoma sample
described here in the patient tumor were preserved in the
orthotopic xenograft. The histopathological features of the patient
tumor were preserved in the xenograft with robust expression of
antigens typically found in neuroblastoma including synaptophy-
sin and chromogranin. Importantly, key subcellular features of
neuroblastoma tumors including dense core vesicles were found
in the primary patient tumor and the xenograft. The gene expres-
sion proﬁle and DNA methylation proﬁle of the xenograft were
similar to the patient's primary tumor. The differences that were
observed were associated with normal cells found within the
tumor such as macrophages and vascular endothelial cells. The
xenografted tumor does have vasculature and inﬁltration of
macrophages but those are contributed by the mouse and are
therefore not detected in the human array platforms. As in the
patient, the xenografted tumor was aggressive with metastasis to
the liver, spleen, lymph nodes and other sites in over 70% of mice.
While some of the metastatic lesions could have been the result of
seeding associated with ultrasound guided para-adrenal injec-
tions, the cells in lymph node and lung were likely the result of
dissemination from the primary tumor. Also, even in the liver, the
cells inﬁltrated into the tissue suggesting that they retained the
ability to disrupt the cell–cell junctions and invade normal organs
associated with neuroblastoma metastasis. One notable exception
for metastasis was the bone marrow, which is a common site of
metastasis in human neuroblastoma. The xenografted tumors did
not metastasis as efﬁciently to the bone marrow as noted in other
orthotopic neuroblastoma xenografts (Braekeveldt et al., 2015). It
is possible that the immunocompromised status of these mice
prevents the tumors from metastasizing to the bone marrow
because the microenvironment is altered. Future studies with
humanized mice will be useful to test this hypothesis.
Exome sequencing identiﬁed a series of SNVs that were unique to
the xenograft. They were not present in the whole genome sequence
data from the original patient's tumor. It is possible that they were
from a minor clone in a distinct region of the primary patient tumor
that had a growth advantage in the xenograft or that they were
acquired in the xenograft with passage. It is not known if those SNVs
contribute to tumor progression or if they are simply passenger
mutations. At the chromosomal level, there were no signiﬁcant
changes in copy number variations, structural variations or aneu-
ploidy in the xenograft compared to the primary tumor. These data
show the value of comprehensive molecular, cellular and genetic
characterization of orthotopic xenografts to ensure that they faithfully
recapitulate the patient tumor. All of the tumors described in the
companion paper titled “The Childhood Solid Tumor Network: A New
Resource for the Developmental Biology and Oncology Research
Communities” are currently undergoing similar characterization.
Importantly, in a previous study published by Braekeveldt, they
also showed that patient-derived neuroblastoma xenografts
retained molecular, cellular, genetic and histopathologic features
of the primary tumor (Braekeveldt et al., 2015). Thus, in two
independent laboratories, neuroblastoma xenografts have been
generated that retain the genetic and phenotypic features of the
patient tumor and can be passaged in vivo and in culture. These
patient derived xenografts have many advantages over cell lines
that have been maintained in culture for many years and will
provide a useful resource for the biomedical research community.
4.2. Preclincial testing and drug screening using orthotopic
xenografts
In order to demonstrate the feasibility of using the orthotopic
xenografts for preclinical studies, we tested standard of care induc-
tion chemotherapy and molecular targeted therapeutic combinations
previously shown to have activity for neuroblastoma in mouse
models. Key features of our study are the use of AUC guided dosing
and clinically relevant schedules of drug combinations. Also, the mice
were randomized into different treatment arms and the study was
performed double blind to minimize any experimental bias. We also
entered all the primary data from each mouse and the histopatho-
logical analysis of the individual tumors into a central database using
OpenClinica. This allows us to share the raw data with other
investigators and provides a convenient platform to test hypotheses
and identify biologically relevant correlations. Finally, we showed that
the orthotopic xenografts can be cultured as primary acute cultures
and used to test drug sensitivity in vitro. While this does not
recapitulate the complexity of the tumor microenvironment in vivo,
it does allow researchers to test a large number of individual drugs
quickly. In addition, this technique will also allow for more sophis-
ticated in vitro studies of drug combinations as novel agents become
available. Promising new therapeutic agents can then be efﬁciently
moved in vivo using our standard procedure for preclinical testing.
This is also important because it suggests that the agents tested here
(OSI-906, BEZ235 and BKM120) have very limited efﬁcacy in this
high-risk orthotopic neuroblastoma xenograft model when combined
with induction chemotherapy.
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